Clinical trial
Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and…
NCT00410592 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00410592 |
|---|---|
| Title | Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD |
| Official title | A Randomized, Open-Label, Comparative 3-Way Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in Hispanic Patients With Symptomatic GERD |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Gastroesophageal Reflux Disease |
| Intervention type | Drug |
| Interventions | Esomeprazole 40mg, Pantoprazole 40mg, Lansoprazole 30mg |
| Enrollment | 90 |
| Start date | Oct 1, 2006 |
| Completion | May 1, 2007 |
| First posted | Dec 13, 2006 |
| Last update posted | Mar 11, 2009 |
| Countries | Puerto Rico, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: